Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024

Cerus Corporation (NASDAQ:CERS) is a favorite amongst institutional investors who own 64%

Cerus Corporation: Strong Buy Rating Amidst Growth and Path to Profitability

Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients

Cerus’s Strong Q4 Performance and Positive 2024 Outlook Prompt ‘Buy’ Rating

Insider Sell: President and CEO William Greenman Sells 125,926 Shares of Cerus Corp (CERS)

Insider Sell: COO Vivek Jayaraman Sells 53,041 Shares of Cerus Corp (CERS)

Analysts Offer Insights on Healthcare Companies: iCAD (ICAD), Mustang Bio (MBIO) and Cerus (CERS)

Earnings Release: Here's Why Analysts Cut Their Cerus Corporation (NASDAQ:CERS) Price Target To US$4.13

Cerus Corp (CERS) Posts Narrowed Q4 Net Loss and Achieves Adjusted EBITDA Breakeven

Cerus Corporation (NASDAQ:CERS) Q4 2023 Earnings Call Transcript

Cerus Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Cerus Corporation’s New Share Price & Shareholder Rights Risk – A Cause for Worry?

Stifel Nicolaus Keeps Their Buy Rating on Cerus (CERS)

Q4 2023 Cerus Corp Earnings Call

Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results